Skip to content

ENSYSCE BIOSCIENCES, INC.: 10-Q filed 2026-08-13

What ENSYSCE BIOSCIENCES, INC. reported in its quarterly report filed 2026-08-13 (fiscal Q2 2026): 33 published measures, 97 facts as tagged in accession 0001493152-26-037817.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-13
Fiscal period
fiscal Q2 2026
Accession
0001493152-26-037817 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ENSYSCE BIOSCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-302,957,273USD
At 2025-12-317,452,479USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-304,068,106USD
At 2025-12-314,567,729USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-30-781,697USD
At 2025-12-313,213,720USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-30676,704USD
At 2025-12-314,310,354USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-5,463,383USD181
2025-01-01 to 2025-06-30-4,414,280USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,164,315USD91
2026-01-01 to 2026-06-302,125,313USD181
2025-04-01 to 2025-06-301,371,438USD91
2025-01-01 to 2025-06-302,691,210USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-301,829,733USD181
2025-01-01 to 2025-06-303,123,778USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-145,847,123USD
At 2025-12-31-139,719,999USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-3013,035,632shares91
2026-01-01 to 2026-06-309,954,626shares181
2025-04-01 to 2025-06-302,202,299shares91
2025-01-01 to 2025-06-301,803,393shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-3013,035,632shares91
2026-01-01 to 2026-06-309,954,626shares181
2025-04-01 to 2025-06-302,202,299shares91
2025-01-01 to 2025-06-301,803,393shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.2USD/shares91
2026-01-01 to 2026-06-30-0.62USD/shares181
2025-04-01 to 2025-06-30-0.79USD/shares91
2025-01-01 to 2025-06-30-2.04USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.2USD/shares91
2026-01-01 to 2026-06-30-0.62USD/shares181
2025-04-01 to 2025-06-30-0.79USD/shares91
2025-01-01 to 2025-06-30-2.04USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-06-30111,063USD
At 2025-12-31124,129USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-3010,613USD181
2025-01-01 to 2025-06-30203,014USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-2,576,389USD91
2026-01-01 to 2026-06-30-6,138,619USD181
2025-04-01 to 2025-06-30-1,750,515USD91
2025-01-01 to 2025-06-30-3,718,026USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-302,846,210USD
At 2025-12-317,245,018USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-304,068,106USD
At 2025-12-314,567,729USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-301,977,629USD
At 2025-12-313,267,610USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-303,740,704USD91
2026-01-01 to 2026-06-308,263,932USD181
2025-04-01 to 2025-06-303,121,953USD91
2025-01-01 to 2025-06-306,409,236USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,471,752USD91
2026-01-01 to 2026-06-305,818,633USD181
2025-04-01 to 2025-06-301,923,430USD91
2025-01-01 to 2025-06-303,808,957USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-3016,227,518shares
At 2025-12-314,574,977shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-30145,063,802USD
At 2025-12-31142,933,260USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2026-06-30-1,110,833USD
At 2026-03-31-669,012USD
At 2025-12-312,884,750USD
At 2025-06-303,060,412USD
At 2025-03-312,720,518USD
At 2024-12-313,379,939USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-12-3183,332USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-301,752,695USD
At 2025-12-312,514,319USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-2,570,875USD91
2026-01-01 to 2026-06-30-6,127,290USD181
2025-04-01 to 2025-06-30-1,733,517USD91
2025-01-01 to 2025-06-30-3,679,090USD181

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-2,570,709USD91
2026-01-01 to 2026-06-30-6,127,124USD181
2025-04-01 to 2025-06-30-1,733,351USD91
2025-01-01 to 2025-06-30-3,678,924USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,268,952USD91
2026-01-01 to 2026-06-302,445,299USD181
2025-04-01 to 2025-06-301,198,523USD91
2025-01-01 to 2025-06-302,600,279USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2026-04-01 to 2026-06-306,533USD91
2026-01-01 to 2026-06-3013,066USD181

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-04-01 to 2026-06-30320USD91
2026-01-01 to 2026-06-304,243USD181
2025-04-01 to 2025-06-303,160USD91
2025-01-01 to 2025-06-307,017USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2026-04-01 to 2026-06-305,834USD91
2026-01-01 to 2026-06-3015,572USD181
2025-04-01 to 2025-06-3021,011USD91
2025-01-01 to 2025-06-3036,890USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-305,514USD91
2026-01-01 to 2026-06-3011,329USD181
2025-04-01 to 2025-06-3016,998USD91
2025-01-01 to 2025-06-3038,936USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-1,355,046USD181
2025-01-01 to 2025-06-30-314,247USD181

Inspect the source

Entity
ENSYSCE BIOSCIENCES, INC. / CIK 0001716947
Captured
2026-09-21T17:24:39.335Z
SEC response SHA-256
28573a09f81da1511239531464c03b2552a3554a684a233653f365b194b6ca0b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001716947.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))